These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8804007)

  • 21. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-flux and low-flux dialysis membranes and levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in children with chronic kidney failure.
    Sawires HK; Mohamed WA; Schaalan MF
    Iran J Kidney Dis; 2012 Sep; 6(5):366-72. PubMed ID: 22976263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD.
    Ginsburg ES; Walsh B; Greenberg L; Price D; Chertow GM; Owen WF
    Kidney Int; 1998 Oct; 54(4):1344-50. PubMed ID: 9767554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is dialysis membrane type responsible for increased circulating adhesion molecules during chronic hemodialysis?
    Mrowka C; Heintz B; Sieberth HG
    Clin Nephrol; 1999 Nov; 52(5):312-21. PubMed ID: 10584995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of two different high-flux dialysis membranes on insulin resistance in non-diabetic end-stage renal disease patients.
    Kara M; Gurluler E; Cakır U
    Ren Fail; 2015; 37(8):1293-6. PubMed ID: 26399977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes.
    Degiannis D; Czarnecki M; Donati D; Homer L; Eisinger RP; Raska K; Raskova J
    Am J Nephrol; 1990; 10(4):276-82. PubMed ID: 2240054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients.
    Heimann P; Josephson MA; Fellner SK; Thistlethwaite JR; Stuart FP; Dasgupta A
    Am J Nephrol; 1991; 11(6):470-4. PubMed ID: 1840233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure.
    Kimak E; Ksiazek A; Solski J
    Clin Chem Lab Med; 2006; 44(1):64-9. PubMed ID: 16375588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of dialysis initiation, duration and frequency of hemodialysis sessions, and membrane flux: a systematic review for a KDOQI clinical practice guideline.
    Slinin Y; Greer N; Ishani A; MacDonald R; Olson C; Rutks I; Wilt TJ
    Am J Kidney Dis; 2015 Nov; 66(5):823-36. PubMed ID: 26498415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis.
    Clark WR; Hamburger RJ; Lysaght MJ
    Kidney Int; 1999 Dec; 56(6):2005-15. PubMed ID: 10594776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients.
    Docci D; Capponcini C; Mengozzi S; Baldrati L; Neri L; Feletti C
    Nephron; 1995; 69(3):323-6. PubMed ID: 7753268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients.
    Gluba-Brzozka A; Franczyk B; Bartnicki P; Rysz-Gorzyn Ska M; Rysz J
    Curr Vasc Pharmacol; 2017; 15(2):123-134. PubMed ID: 27774887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study.
    Dusejovska M; Stankova B; Vecka M; Rychlíkova J; Mokrejsova M; Rychlík I; Zak A
    Curr Vasc Pharmacol; 2018; 16(3):298-305. PubMed ID: 28554308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased lipoprotein-remnant formation in chronic renal failure.
    Nestel PJ; Fidge NH; Tan MH
    N Engl J Med; 1982 Aug; 307(6):329-33. PubMed ID: 7088097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial.
    Santoro A; Mancini E; Bolzani R; Boggi R; Cagnoli L; Francioso A; Fusaroli M; Piazza V; Rapanà R; Strippoli GF
    Am J Kidney Dis; 2008 Sep; 52(3):507-18. PubMed ID: 18617304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
    Pellicano R; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal fat metabolism in chronic renal failure.
    Romics L; Makó J
    Acta Med Acad Sci Hung; 1978; 35(3-4):233-40. PubMed ID: 227218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biological adequacy--what does it mean?].
    Kes P; Basić-Jukić N; Brunetta B
    Acta Med Croatica; 2004; 58(1):1-4. PubMed ID: 15125386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
    Gluba-Brzózka A; Franczyk B; Banach M; Rysz-Górzyńska M
    Int Urol Nephrol; 2017 Jan; 49(1):155-164. PubMed ID: 27942970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.